Why Is Lagevrio So Hard to Find? [Explained for 2026]

If you've been prescribed Lagevrio (molnupiravir) and called around to pharmacies only to come up empty-handed, you're not imagining things. This COVID-19 antiviral pill — made by Merck under an FDA Emergency Use Authorization — has become one of the more frustrating prescriptions to fill in 2026. Here's a clear-eyed look at why that is and what you can do.

What Is Lagevrio, and Who Is It For?

Lagevrio (molnupiravir) is an oral antiviral medication used to treat mild-to-moderate COVID-19 in adults who are at high risk for progression to severe illness — including hospitalization or death. It works by introducing errors into the virus's genetic code, eventually preventing it from replicating. It's taken as four 200 mg capsules twice daily for five days, ideally started within five days of symptom onset.

Lagevrio is a second-line treatment — meaning it's typically prescribed when Paxlovid (the preferred first-line option) is unavailable, contraindicated, or not tolerated. This positioning matters a lot when we talk about why it can be hard to find.

Why Did Government-Distributed Lagevrio Disappear?

For much of 2022 and 2023, Lagevrio was distributed through the U.S. government's pandemic response infrastructure — meaning many patients could get it at no cost through Test to Treat sites, local health departments, and certain pharmacies. That era ended. The government stopped purchasing and distributing Lagevrio through commercial channels in late 2023, and all remaining federally distributed Lagevrio stock expired by February 27, 2025.

Today, Lagevrio is only available through the standard commercial pharmacy supply chain. That means it works just like any other prescription medication — pharmacies order it, stock it, and dispense it. And that transition has created real gaps.

Why Don't Pharmacies Stock Lagevrio Routinely?

Several factors make pharmacies reluctant to keep Lagevrio on the shelf:

Low demand relative to Paxlovid. Because Lagevrio is a second-line treatment, most eligible COVID patients are prescribed Paxlovid first. Lagevrio prescriptions are rarer, so pharmacies stock less of it.

High cost and expiration risk. A full course of Lagevrio retails for over $1,100. Pharmacies risk financial loss if doses expire before a patient needs them.

Unpredictable, surge-driven demand. COVID-19 demand spikes in fall and winter. Pharmacies can deplete limited stock within days during surges, then sit with nothing for weeks.

EUA-only status. Lagevrio has never received full FDA approval — only Emergency Use Authorization. Some pharmacies and insurers treat EUA drugs differently from fully approved medications.

Is There an Official Lagevrio Shortage in 2026?

As of 2026, Lagevrio is not on the FDA's official drug shortage list. That means national supply exists and Merck continues to manufacture and distribute it. However, 'not in shortage' does not mean 'easy to find.' Pharmacy-level stock-outs are common, especially during COVID surges and in rural areas where overall prescription volume is lower.

The real challenge is a distribution and stocking problem, not a manufacturing problem. There's enough Lagevrio being made — it just isn't sitting at every pharmacy counter when you need it.

The 5-Day Window Makes Finding It Urgent

This is the cruelest part of the situation. Lagevrio must be started within five days of symptom onset to be effective. When you're sick, dealing with a diagnosis, and calling pharmacies who keep saying 'we don't have it,' that window can slip away quickly. Studies show that delays in filling COVID antiviral prescriptions are one of the primary reasons eligible patients never get treated.

Who Is Most Likely to Be Prescribed Lagevrio?

Lagevrio is typically prescribed to patients who:

Cannot take Paxlovid due to significant drug interactions (e.g., patients on immunosuppressants, certain cardiac medications, or complex polypharmacy regimens)

Cannot receive IV Remdesivir (Veklury) due to logistical barriers

Are at high risk for severe COVID-19 (age 65+, immunocompromised, chronic conditions like diabetes, heart disease, or COPD)

Live in areas where Paxlovid is also unavailable

What Can You Do If You Can't Find Lagevrio?

The most effective first step is to use medfinder — a service that contacts pharmacies near you to check which ones can fill your prescription. This saves you from calling pharmacy after pharmacy while you're already feeling sick.

Other practical steps include:

Call independent pharmacies and hospital outpatient pharmacies — they are often overlooked but may carry Lagevrio

Ask your prescriber to check with their office or hospital pharmacy network for available stock

Ask about telehealth — some telehealth providers can route prescriptions to pharmacies with confirmed Lagevrio stock

Talk to your doctor about alternatives to Lagevrio if no pharmacy near you has it in stock

The Bottom Line

Lagevrio is hard to find in 2026 because of a combination of low stocking by pharmacies, surge-driven demand spikes, and the expiration of government-distributed supply. There is no manufacturing shortage — but there is a real access problem at the local pharmacy level. For tips on locating it quickly, see our guide on how to find Lagevrio in stock near you.